Takeda’s Fruzaqla approved by EC to treat metastatic colorectal cancer in adults

24 Jun 2024
pmlive.com
Drug ApprovalClinical ResultAccelerated Approval
Takeda’s Fruzaqla approved by EC to treat metastatic colorectal cancer in adults
Preview
Source: PMLiVE
Takeda’s Fruzaqla (fruquintinib) has been approved by the European Commission (EC) to treat adults with previously treated metastatic colorectal cancer (CRC).
Patients eligible for the VEGF inhibitor will have received available standard therapies, including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, and anti-VEGF and anti-EGFR agents, and will have progressed on or been intolerant to either trifluridine-tipiracil or regorafenib.
CRC, which begins in either the colon or rectum, was the second most common cancer in Europe in 2022, with approximately 538,000 new cases of the disease diagnosed that year.
Although early-stage CRC can be surgically resected, Takeda outlined that metastatic CRC “remains an area of high unmet need with poor outcomes and limited treatment options”.
The EC’s decision follows a recent recommendation from the European Medicines Agency’s human medicines committee and was based on positive results from the late-stage FRESCO-2 trial, which evaluated Fruzaqla plus best supportive care (BSC) versus placebo plus BSC in patients with previously treated metastatic CRC.
The study met all its primary and key secondary efficacy endpoints and demonstrated consistent benefit among patients treated with Fruzaqla regardless of prior therapy type, Takeda said, adding that the drug demonstrated a manageable profile.
Teresa Bitetti, president of the global oncology business unit at Takeda, said the approvals marked “an important moment for the colorectal cancer community in the EU”.
“We look forward to offering patients a novel treatment option that has a manageable safety profile and can be effective regardless of the prior types of therapies they have received,” she said.
Fruzaqla received approval from the US Food and Drug Administration (FDA) in November to treat adults with metastatic CRC who have been previously treated with chemotherapy, an anti-VEGF therapy, and in some cases, an anti-EGFR therapy.
The latest authorisation for the therapy comes just two months after Takeda’s Entyvio (vedolizumab) was approved by the FDA for subcutaneous administration in adults with moderately to severely active Crohn’s disease.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.